Provista develops and commercializes, through its own CLIA compliant laboratory, breakthrough diagnostic tests for significant medical illnesses, primarily where no clinical test exists. It was established and incorporated in 2007 as a means of consolidating three separate diagnostic technology companies being operated and managed by Provista Management; i.e. GW Medical Technologies LLC, est. 2004 (LymPro Test), Biomarker Technologies LLC, est. 2004 (BT Test) and RCP Diagnostics LLC, est. 2005 (RCP Test). Since then Provista has brought on an two additional technology for development called the LC Sentinel Test, a blood test for the dection of Ovarian Cancer;